Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Firm submits PMA supplement for use of its LaserScan LSX excimer laser in LASIK surgery to correct hyeropia of +0.5D to +8.0D and hyperopic astigmatism of up to +6.0D. LaserSight submitted a PMA supplement for LASIK treatment of myopia in December 2000. Approval of a March 2000 PMA supplement submission for treatment of astigmatism using photorefractive keratectomy has been delayed by questions raised by FDA (1"The Gray Sheet" Feb. 19, 2001, In Brief)

You may also be interested in...


Firm preparing response to Feb. 7 questions by FDA on March 2000 PMA supplement for the LaserScan LSX for treatment of astigmatism using photorefractive keratectomy. In December, the firm filed a separate PMA supplement for LASIK treatment of myopia and myopic astigmatism

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts